Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

HIV infection, hypercoagulability and ischaemic stroke in adults at the University Teaching Hospital in Zambia: a case control study

Authors: Stanley Zimba, Patrice Mukomena Ntanda, Shabir Lakhi, Masharip Atadzhanov

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

In Zambia, 14.2% of adults have HIV/AIDS. There has been a substantial and significant increase in patients hospitalized for ischaemic stroke with co-existing HIV infection. However, little is known about the mechanism of stroke in these HIV + ve patients let alone studied in our region. The aim of this pilot study was to explore the association of hypercoagulability state in HIV + ve patients with ischaemic stroke. This was achieved by comparing hypercoagulability state markers between HIV + ve ischaemic stroke patients with HIV-ve and HIV + ve patients with and without ischaemic stroke respectively.

Methods

A matched case control study in which a total of 52 HIV + ve patients with ischaemic stroke were prospectively compared with control groups for the presence of protein S, protein C deficiencies and hyperhomocysteinaemia. The control groups comprised an equal number of consecutively matched for age and sex HIV-ve and HIV + ve patients with and without ischaemic stroke respectively. Data was analysed in contingency tables using Paired t- test, Chi square and conditional logistic regression.

Results

Ischaemic stroke of undetermined aetiology occurred more frequently in HIV + ve compared to HIV-ve patients (p < 0.001). In addition, protein S deficiency and Hyperhomocysteinaemia were more prominent in HIV + ve than HIV-ve ischaemic stroke patients (P = 0.011). There was no difference in the presence of hyperhomocysteinaemia or protein S deficiency in HIV + ve patients with or without ischaemic stroke. Protein C deficiency was not noted to be significantly different between the cases and the two control arms.

Conclusion

Protein S deficiency and hyperhomocysteinaemia were associated with HIV infection, but not stroke in our study population. However, this is an area that requires extensive research and one that we cannot afford to ignore as it is an important bridge to all cardiovascular and cerebrovascular diseases.
Literature
3.
go back to reference Atadzhanov M, Mukomena PN, Lakhi S, et al. Stroke characteristics and outcomes of adults patients admitted to the University teaching hospital, Lusaka, Zambia. Open access. 2012;5:3–8. Atadzhanov M, Mukomena PN, Lakhi S, et al. Stroke characteristics and outcomes of adults patients admitted to the University teaching hospital, Lusaka, Zambia. Open access. 2012;5:3–8.
5.
go back to reference Gutierrez J, Goldman J, Marshall RS, et al. Brain arterial remodelling contribution to nonembolic brain infarcts in patients with HIV. Neurology. 2015;85:1139–45.CrossRefPubMedPubMedCentral Gutierrez J, Goldman J, Marshall RS, et al. Brain arterial remodelling contribution to nonembolic brain infarcts in patients with HIV. Neurology. 2015;85:1139–45.CrossRefPubMedPubMedCentral
6.
7.
go back to reference Kengne AP, Anderson CS. The neglected burden of stroke in sub-Saharan Africa. Int J Stroke. 2006;1:180–90.CrossRefPubMed Kengne AP, Anderson CS. The neglected burden of stroke in sub-Saharan Africa. Int J Stroke. 2006;1:180–90.CrossRefPubMed
8.
go back to reference Heikinheimo T, Chimbayo D, Kumwenda JJ. Stroke outcomes in Malawi, a country with high prevalence of HIV: a prospective follow-up study. Open access. 2012;7:3. Heikinheimo T, Chimbayo D, Kumwenda JJ. Stroke outcomes in Malawi, a country with high prevalence of HIV: a prospective follow-up study. Open access. 2012;7:3.
9.
go back to reference Connor M, Rheeder P, Bryer A. The South African stroke risk in general practice study. S Afr Med J. 2005;95:334–9.PubMed Connor M, Rheeder P, Bryer A. The South African stroke risk in general practice study. S Afr Med J. 2005;95:334–9.PubMed
10.
go back to reference Connor MD, Walker R, Modi G, Warlow CP. Burden of stroke in black populations in sub-Saharan Africa. Lancet Neurol. 2007;6:269–78.CrossRefPubMed Connor MD, Walker R, Modi G, Warlow CP. Burden of stroke in black populations in sub-Saharan Africa. Lancet Neurol. 2007;6:269–78.CrossRefPubMed
11.
go back to reference Dobbs MR, Berger JR. Stroke in HIV infection and AIDS. Expert Rev Cardiovasc Ther. 2009;7:1263–71.CrossRefPubMed Dobbs MR, Berger JR. Stroke in HIV infection and AIDS. Expert Rev Cardiovasc Ther. 2009;7:1263–71.CrossRefPubMed
12.
go back to reference Ortiz G, Koch S, Romano JG. Mechanisms of ischaemic stroke in HIV-infected patients. Neurology. 2007;68(16):1257–61.CrossRefPubMed Ortiz G, Koch S, Romano JG. Mechanisms of ischaemic stroke in HIV-infected patients. Neurology. 2007;68(16):1257–61.CrossRefPubMed
13.
go back to reference Smego RA, Orlovic D. Hypercoagulability due to protein S deficiency in HIV-seropositive patients. Int J Collab Res Intern Med Public Health. 2009. http://www.thefreelibrary.com/terms.aspx. Accessed 15 Jan 2014 Smego RA, Orlovic D. Hypercoagulability due to protein S deficiency in HIV-seropositive patients. Int J Collab Res Intern Med Public Health. 2009. http://​www.​thefreelibrary.​com/​terms.​aspx.​ Accessed 15 Jan 2014
14.
go back to reference Dichgans M, Markus HS. Genetic association studies in stroke: methodological issues and proposed standard criteria. Stroke. 2005;36:2027–31. doi:10.1161/01.STR. 0000177498. 21594.CrossRefPubMed Dichgans M, Markus HS. Genetic association studies in stroke: methodological issues and proposed standard criteria. Stroke. 2005;36:2027–31. doi:10.1161/01.STR. 0000177498. 21594.CrossRefPubMed
15.
go back to reference Solberg HE. Approved recommendation on the theory of Reference values. Part 5. Statistical treatment of collected Reference values. Determination of Reference Limits. 1987;25(suppl 1):645–56. Solberg HE. Approved recommendation on the theory of Reference values. Part 5. Statistical treatment of collected Reference values. Determination of Reference Limits. 1987;25(suppl 1):645–56.
16.
go back to reference Adams HP, Bendixen BH, Kappelle LJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24:35–41.CrossRefPubMed Adams HP, Bendixen BH, Kappelle LJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24:35–41.CrossRefPubMed
17.
go back to reference Goldstein LB, Jones MR, Matchar DB. Improving the reliability of stroke subgroup classification using the trial of ORG 10172 in acute stroke treatment (TOAST) criteria editorial comment: classifying themechanisms of ischemic stroke. Stroke. 2001;32:1091–7.CrossRefPubMed Goldstein LB, Jones MR, Matchar DB. Improving the reliability of stroke subgroup classification using the trial of ORG 10172 in acute stroke treatment (TOAST) criteria editorial comment: classifying themechanisms of ischemic stroke. Stroke. 2001;32:1091–7.CrossRefPubMed
18.
go back to reference Tipping B, de Villiers L, Wainwright H. Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry. 2007;78(12):1320–4.CrossRefPubMedPubMedCentral Tipping B, de Villiers L, Wainwright H. Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry. 2007;78(12):1320–4.CrossRefPubMedPubMedCentral
19.
go back to reference Remkova A. Diagnostic approach to hypercoagulable states. Bratisl Lek Listy. 2006;107(8):292–5.PubMed Remkova A. Diagnostic approach to hypercoagulable states. Bratisl Lek Listy. 2006;107(8):292–5.PubMed
20.
go back to reference Kloppenborg PR, Geerlings MI, Visseren FL, et al. Homocysteine and progression of generalized small-vessel disease. Neurology. 2014;82:777–83.CrossRefPubMed Kloppenborg PR, Geerlings MI, Visseren FL, et al. Homocysteine and progression of generalized small-vessel disease. Neurology. 2014;82:777–83.CrossRefPubMed
21.
go back to reference Jeon SB, Kang WD, Kim JS, Kwon SU. Homocysteine, small-vessel disease, and atherosclerosis. Neurology. 2014;83:695–701.CrossRefPubMed Jeon SB, Kang WD, Kim JS, Kwon SU. Homocysteine, small-vessel disease, and atherosclerosis. Neurology. 2014;83:695–701.CrossRefPubMed
22.
go back to reference Coria-Ramirez E, Cisneros LN, Trevino-Perez S, et al. Effect of highly active antiretroviral therapy on homocysteine plasma concentrations in HIV-1 infected patients. J Acquir Immune Defic Syndr. 2010;54:477–81.CrossRefPubMed Coria-Ramirez E, Cisneros LN, Trevino-Perez S, et al. Effect of highly active antiretroviral therapy on homocysteine plasma concentrations in HIV-1 infected patients. J Acquir Immune Defic Syndr. 2010;54:477–81.CrossRefPubMed
23.
go back to reference Mochan A, Modi M, Modi G. Protein S deficiency in HIV associated ischaemic stroke: an epiphenomenon of HIV infection. J Neurol Neurosurg Psychiatry. 2005;76:1455–6.CrossRefPubMedPubMedCentral Mochan A, Modi M, Modi G. Protein S deficiency in HIV associated ischaemic stroke: an epiphenomenon of HIV infection. J Neurol Neurosurg Psychiatry. 2005;76:1455–6.CrossRefPubMedPubMedCentral
24.
go back to reference Alain L, Alessi MC, Poizot-Martin I. Protein S deficiency and HIV infection. N Engl J Med. 1991;324:1220. Alain L, Alessi MC, Poizot-Martin I. Protein S deficiency and HIV infection. N Engl J Med. 1991;324:1220.
25.
go back to reference Sorice M, Griggi T, Arcieri P. Protein S and HIV infection. The role of anticardiolipin and anti-protein S antibodies. Thromb Res. 1994;73(3–4):165–75.CrossRefPubMed Sorice M, Griggi T, Arcieri P. Protein S and HIV infection. The role of anticardiolipin and anti-protein S antibodies. Thromb Res. 1994;73(3–4):165–75.CrossRefPubMed
27.
go back to reference Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke. 1992;23:221–3.CrossRefPubMed Brass LM, Isaacsohn JL, Merikangas KR, Robinette CD. A study of twins and stroke. Stroke. 1992;23:221–3.CrossRefPubMed
28.
go back to reference Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke. 2002;33:769–74.CrossRefPubMed Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke. 2002;33:769–74.CrossRefPubMed
30.
go back to reference Hascombe KB, Traylor M, Hysi PG, et al. Genetic factors influencing coagulation factor XII B-subunit contribute to risk of ischaemic stroke. Stroke. 2015;46:2069–74. American Heart AssociationCrossRef Hascombe KB, Traylor M, Hysi PG, et al. Genetic factors influencing coagulation factor XII B-subunit contribute to risk of ischaemic stroke. Stroke. 2015;46:2069–74. American Heart AssociationCrossRef
Metadata
Title
HIV infection, hypercoagulability and ischaemic stroke in adults at the University Teaching Hospital in Zambia: a case control study
Authors
Stanley Zimba
Patrice Mukomena Ntanda
Shabir Lakhi
Masharip Atadzhanov
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2455-0

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine